132
Views
11
CrossRef citations to date
0
Altmetric
Research Articles

Development of an optimized febuxostat self-nanoemulsified loaded transdermal film: in-vitro, ex-vivo and in-vivo evaluation

ORCID Icon, ORCID Icon, ORCID Icon, , , , , ORCID Icon & show all
Pages 326-331 | Received 30 Sep 2019, Accepted 01 Dec 2019, Published online: 17 Dec 2019

References

  • Ah Y-C, Choi J-K, Choi Y-K, Ki H-M, Bae J-H. 2010. A novel transdermal patch incorporating meloxicam: in vitro and in vivo characterization. Int J Pharm. 385(1–2):12–19.
  • Ahmed OAA, Afouna MI, El-Say KM, Abdel-Naim AB, Khedr A, Banjar ZM. 2014a. Optimization of self-nanoemulsifying systems for the enhancement of in vivo hypoglycemic efficacy of glimepiride transdermal patches. Expert Opin Drug Deliv. 11:1005–1013.
  • Ahmed OAA, Badr-Eldin SM. 2018. In situ misemgel as a multifunctional dual-absorption platform for nasal delivery of raloxifene hydrochloride: formulation, characterization, and in vivo performance. IJN. 13:6325–6335.
  • Ahmed OAA, Badr-Eldin SM, Tawfik MK, Ahmed TA, El-Say KM, Badr JM. 2014b. Design and optimization of self-nanoemulsifying delivery system to enhance quercetin hepatoprotective activity in paracetamol-induced hepatotoxicity. J Pharm Sci. 103(2):602–612.
  • Ahmed OAA, El-Say KM, Aljaeid BM, Badr-Eldin SM, Ahmed TA. 2018. Optimized vinpocetine-loaded vitamin E D-α-tocopherol polyethylene glycol 1000 succinate-alpha lipoic acid micelles as a potential transdermal drug delivery system: in vitro and ex vivo studies. IJN. 14:33–43.
  • Aldawsari HM, Elfaky MA, Fahmy UA, Aljaeid BM, Alshareef OA, El-Say KM. 2018. Development of a fluvastatin-loaded self-nanoemulsifying system to maximize therapeutic efficacy in human colorectal carcinoma cells. J Drug Deliv Sci Technol. 46:7–13.
  • Alexander A, Dwivedi S, Ajazuddin , Giri TK, Saraf S, Saraf S, Tripathi DK. 2012. Approaches for breaking the barriers of drug permeation through transdermal drug delivery. J Control Release. 164:26–40.
  • Alkilani AZ, McCrudden MTC, Donnelly RF. 2015. Transdermal drug delivery: innovative pharmaceutical developments based on disruption of the barrier properties of the stratum corneum. Pharmaceutics. 7(4):438–470.
  • Badr-Eldin SM, Ahmed OAA. 2016. Optimized nano-transfersomal films for enhanced sildenafil citrate transdermal delivery: ex vivo and in vivo evaluation. Drug Des Devel Ther. 10:1323–1333.
  • Basalious EBEB, Shawky N, Badr-Eldin SMSM. 2010. SNEDDS containing bioenhancers for improvement of dissolution and oral absorption of lacidipine. I: development and optimization. Int J Pharm. 391(1–2):203–211.
  • Behera SK, Meena H, Chakraborty S, Meikap BC. 2018. Application of response surface methodology (RSM) for optimization of leaching parameters for ash reduction from low-grade coal. Int J Min Sci Technol. 28(4):621–629.
  • Benson H. 2005. Transdermal drug delivery: penetration enhancement techniques. CDD. 2(1):23–33.
  • Biau DJ, Jolles BM, Porcher R. 2010. P value and the theory of hypothesis testing: an explanation for new researchers. Clin Orthop Relat Res. 468(3):885–892.
  • Cevc G, Schätzlein A, Blume G. 1995. Transdermal drug carriers: basic properties, optimization and transfer efficiency in the case of epicutaneously applied peptides. J Control Release. 36(1-2):3–16.
  • Cho C-W, Choi J-S, Yang K-H, Shin S-C. 2009. Enhanced transdermal controlled delivery of glimepiride from the ethylene-vinyl acetate matrix. Drug Deliv. 16(6):320–330.
  • Damarla M, Johnston LF, Liu G, Gao L, Wang L, Varela L, Kolb TM, Kim BS, Damico RL, Hassoun PM. 2017. XOR inhibition with febuxostat accelerates pulmonary endothelial barrier recovery and improves survival in lipopolysaccharide‐induced murine sepsis. Physiol Rep. 5(15):pii: e13377.
  • Date AA, Nagarsenker MS. 2007. Design and evaluation of self-nanoemulsifying drug delivery systems (SNEDDS) for cefpodoxime proxetil. Int J Pharm. 329(1–2):166–172.
  • El-Say KM, Ahmed TA, Ahmed OAA, Hosny KM, Abd-Allah FI. 2017. Self-nanoemulsifying lyophilized tablets for flash oral transmucosal delivery of vitamin K: development and clinical evaluation. J Pharm Sci. 106:2447–2456.
  • El-Say KM, Ahmed TA, Badr-Eldin SM, Fahmy U, Aldawsari H, Ahmed OAA. 2015. Enhanced permeation parameters of optimized nanostructured simvastatin transdermal films: ex vivo and in vivo evaluation. Pharm Dev Technol. 20(8):919–926.
  • Fahmy UA, Ahmed OA, Hosny K. 2014. Development and evaluation of avanafil self-nanoemulsifying drug delivery system with rapid onset of action and enhanced bioavailability. AAPS PharmSciTech. 16(1):53–58.
  • Fahmy UA, Aljaeid BM. 2018. Tadalafil transdermal delivery with alpha-lipoic acid self nanoemulsion for treatment of erectile dysfunction by diabetes mellitus. Int J Pharmacol. 14(7):945–951.
  • Hosmer DW, Hosmer T, Le Cessie S, Lemeshow S. 1997. A comparison of goodness‐of‐fit tests for the logistic regression model. Statist Med. 16(9):965–980.
  • Khosravan R, Grabowski BA, Mayer MD, Wu J-T, Joseph-Ridge N, Vernillet L. 2006. The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. J Clin Pharmacol. 46(1):88–102.
  • Kreilgaard M. 2002. Influence of microemulsions on cutaneous drug delivery. Adv Drug Deliv Rev. 54(Suppl 1):S77–S98.
  • Morales JO, Fathe KR, Brunaugh A, Ferrati S, Li S, Montenegro-Nicolini M, Mousavikhamene Z, McConville JT, Prausnitz MR, Smyth HDC. 2017. Challenges and future prospects for the delivery of biologics: oral mucosal, pulmonary, and transdermal routes. AAPS J. 19(3):652–668.
  • Mukthinuthalapati MA, Bandaru SPK, Bukkapatnam V, Mohapatro C. 2013. Development and validation of a stability-indicating RP-HPLC method for the determination of febuxostat (a xanthine oxidase inhibitor). J Chromatogr Sci. 51(10):931–938.
  • Nazari-Vanani R, Azarpira N, Heli H, Karimian K, Sattarahmady N. 2017. A novel self-nanoemulsifying formulation for sunitinib: Evaluation of anticancer efficacy. Coll Surf B Biointerf. 160:65–72.
  • Osman A-MM, Al-Kreathy HM, Al-Zahrani A, Ahmed OA, Ramadan WS, Elshal MF, Al-Harthi SE, Ali AS, Khan LM. 2017. Enhancement of efficacy and reduced toxicity of cisplatin through self nanoemulsifying drug delivery system (SNEDDS). Int J Pharmacol. 13:292–302.
  • Qian J, Meng H, Xin L, Xia M, Shen H, Li G, Xie Y. 2017. Self-nanoemulsifying drug delivery systems of myricetin: Formulation development, characterization, and in vitro and in vivo evaluation. Coll Surf B Biointerf. 160:101–109.
  • Ramachandran C, Fleisher D. 2000. Transdermal delivery of drugs for the treatment of bone diseases. Adv Drug Deliv Rev. 42(3):197–223.
  • Tsuruta Y, Mochizuki T, Moriyama T, Itabashi M, Takei T, Tsuchiya K, Nitta K. 2014. Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease. Clin Rheumatol. 33(11):1643–1648.
  • Vaka V, Inamadugu J, Pilli N, Ramesh M, Katreddi H. 2013. A sensitive LC-MS/MS method for the quantification of febuxostat in human plasma and its pharmacokinetic application. Biomed Chromatogr. 27(11):1406–1412.
  • Wang L, Dong J, Chen J, Eastoe J, Li X. 2009. Design and optimization of a new self-nanoemulsifying drug delivery system. J Colloid Interface Sci. 330(2):443–448.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.